Space Viruses: How Microgravity is Reshaping the Fight Against Antibiotic Resistance
Researchers have discovered that viruses infecting bacteria behave differently in the unique environment of space, potentially offering new strategies in the escalating battle against antibiotic-resistant infections. Experiments aboard the International Space Station (ISS) have revealed that viruses, known as bacteriophages, evolve to become more effective at infecting bacteria in microgravity and these space-adapted viruses demonstrate increased potency against drug-resistant strains back on Earth.
The ISS as a Battlefield for Bacteria and Viruses
A study published in the journal PLOS Biology focused on the interaction between Escherichia coli (E. Coli) and the T7 bacteriophage, a virus that specifically infects this common bacterium.1 Identical sets of E. Coli were infected with T7, with one set sent to the ISS and a control group remaining in a laboratory on Earth. Over generations, both sets evolved as the bacteria and viruses clashed, but the microgravity environment of space significantly altered the course of their evolution.
Slower Infection, Sharper Viruses
The research team observed that infection rates were slower in microgravity. While the T7 phages successfully infected E. Coli on the ISS, the process took longer compared to the Earth-based samples. This delay is attributed to the lack of fluid mixing in microgravity, which reduces the frequency of collisions between viruses and bacteria.1 Yet, the viruses adapted to this slower environment, ultimately becoming more efficient at infecting bacteria.
Genetic Mutations: A Tale of Adaptation
Genome sequencing revealed distinct genetic changes in both the viruses and bacteria exposed to microgravity. The space-exposed phages developed mutations that enhanced their ability to bind to bacterial receptors and initiate infection. Simultaneously, the E. Coli acquired mutations that altered their receptors, aiding in survival against both the microgravity conditions and the viral attack.4 This represents a classic evolutionary arms race, but the specific patterns of change differed significantly from those observed in the Earth-grown populations.
Space-Trained Viruses Combat Earthly Infections
Remarkably, when the ISS-evolved phages were returned to Earth and tested against strains of E. Coli known to cause urinary tract infections (UTIs) – strains typically resistant to standard T7 phages – they demonstrated increased effectiveness.3 The viruses, adapted to the slow-paced environment of space, proved more potent against these stubborn infections on Earth.
Implications for Phage Therapy
This discovery holds significant promise for the field of phage therapy, which utilizes viruses to target and kill harmful bacteria. As antibiotic resistance continues to rise, phage therapy is gaining renewed interest due to its precision and specificity. Unlike broad-spectrum antibiotics, phages typically target specific bacterial strains, minimizing disruption to the body’s beneficial microbiome.2 The ISS study suggests that microgravity could help refine phages to target new bacterial strains, including those resistant to conventional phages.
Challenges and Future Directions
While promising, utilizing space for phage evolution presents practical challenges, including the high cost of launching experiments to the ISS and the need for stringent safety protocols. Researchers are exploring whether similar adaptive effects can be replicated using simulated microgravity environments on Earth, such as rotating wall vessels.2
Future research will focus on identifying the specific mutations that enhanced the effectiveness of the space-evolved phages and recreating those changes through genetic engineering. Experiments with other clinically relevant bacteria are as well planned to determine if similar evolutionary responses occur in microgravity. The ultimate goal is to develop a catalog of phages whose infection mechanisms were originally shaped in orbit and then refined on Earth, potentially offering a new arsenal in the fight against drug-resistant infections.